INDIANAPOLIS — In response to pressure from lawmakers in Congress, Eli Lilly and Company is rolling out a cheaper insulin product for diabetic patients.
The Indianapolis-based big pharma company will start selling Insulin Lispro, which they say will start selling at $137.35 per vial. In 2015, insulin made by Eli Lilly cost over $230.
“We’ve engaged in discussions about the price of insulin with many different stakeholders in America’s health care system,” said David Ricks, Lilly’s chairman and chief executive officer. “We’re eager to bring forward a low-priced rapid-acting insulin.”
Last week, the CEO’s of seven big pharma companies were called to testify before Congress on just why the price for insulin was so high. Lilly was not one of those companies, but they were sent a letter from Congress asking for information on their price for insulin.
RELATED | Eli Lilly Avoids Insulin Price Hearing In Front of Congress
“While this change is a step in the right direction, all of us in the health care community must do more to fix the problem of high out-of-pocket costs for Americans living with chronic conditions,” Ricks said. “We hope our announcement is a catalyst for positive change across the U.S. health care system.”
Lilly will also have its original, more expensive product, Humalog, still available for those who wish to keep using it.
(PHOTO: Niklas Halle’n/Getty Images)
